(Circulation. 2000;102:405.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Body Composition and Prevalence of Left Ventricular Hypertrophy
From the Institute of Epidemiology and Social Medicine, Clinical Epidemiology Unit, University of Münster (B.K., H.-W.H.); the Institute of Epidemiology, GSF- National Research Center, München-Neuherberg (B.G., A.D.); the Department of Internal Medicine II, University of Regensburg (M.M., U.B., H.S.); and the Department of Internal Medicine I, Central Hospital, Augsburg (B.K.), Germany.
Correspondence to Hans-Werner Hense, MD, Institut für Epidemiologie und Sozialmedizin, Bereich Klinische Epidemiologie, University of Münster, Domagkstreet 3, D 48129 Münster, Germany. E-mail hense{at}uni-muenster.de
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Fat-free mass (FFM) has been proposed as an optimal normalization of left ventricular (LV) mass to body size. We sought to evaluate the novel FFM-based criteria of LV hypertrophy (LVH).
Methods and Results—A population sample of 1371 men and women aged 25 to 74 years was examined by echocardiography and bioelectrical impedance analysis. Internal partition values for LVH were generated in a healthy population subgroup on the basis of LV mass divided by FFM and by the traditional indexations to body height, height2.7, and body surface area. In contrast to the sex-specific criteria required by traditional indexations, the value of LV mass/FFM that divided individuals with and without LVH was identical for men and women (4.1 g/kg). Estimates of LVH prevalence varied significantly by type of indexation used, internally or externally derived cut points, and by population subgroups. Differences were pronounced among hypertensives and the obese. Thus, the application of LV mass/FFM more than halved the risk of LVH in obese versus nonobese women (odds ratio, 2.5; 95% confidence interval, 1.6 to 4.0) compared with criteria based on LV mass/height2.7 (odds ratio, 5.5; 95% confidence interval, 3.6 to 8.3). Implications among hypertensives were less marked.
Conclusions—Indexation of LV mass to FFM eliminates sex-specific LVH criteria. The proportion of individuals defined as having LVH using the new criteria deviate markedly from traditional indexations. Prospective investigations will be needed to identify the prognostic implications of different indexations, especially in subgroups such as the obese.
Key Words: hypertrophy • fat-free mass • obesity • epidemiology
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Clinical studies in patient groups1 2 3 4 5 and population-based epidemiological studies6 7 8 9 provide evidence that increased left ventricular (LV) mass is an independent risk factor for cardiovascular morbidity and mortality. The risk increases continuously as LV mass rises,4 7 with no indication of a threshold to clearly separate normal from abnormal LV mass dimensions. When defining the range of normal LV mass, individual body size and composition must be taken into consideration because metabolic demand and perfusion needs vary with stature and determine the physiological adaptation of heart size. However, the most appropriate method of adjusting LV mass for body size remains uncertain. In early reports, LV mass was commonly indexed to body surface area (BSA).5 10 To preclude a tendency to misclassify the degree of hypertrophy in the presence of obesity,11 12 13 indexes to body height and to exponentials of body height (named allometric signals) have been invoked to better account for the nonlinear associations of body size with LV mass.5 12 13 14 15 More recent investigations have suggested that the normalization of LV mass to fat-free mass (FFM) is theoretically an even more promising option.12 14 15 16 17 18 19
However, the assessment of FFM in larger studies has long been hampered by technical impediments. The advent of bioelectrical impedance analysis (BIA) now provides a validated20 21 22 23 and easily applicable method of measuring FFM.18 19 In the present investigation, we used BIA to compute individual FFM values, and we derived criteria for LV hypertrophy (LVH) on the basis of the values of the ratio of LV mass/FFM. We evaluated how these novel criteria compared with traditional indexation methods and how they affected the estimation of LVH prevalences in a large population sample.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population
The third survey of the Monitoring of Trends and Determinants of Cardiovascular Disease (MONICA) Augsburg Project took place from October 1994 to June 1995. The Augsburg Project is part of the international collaborative World Health Organization MONICA Study.24 The study design, sampling frame, and data collection have been described in detail elsewhere.24 25 26 Briefly, 6640 individuals aged 25 to 74 years were randomly sampled by a 2-stage, age- and sex-stratified cluster sampling from the population registry. A total of 4856 men and women (response rate, 74.9%) participated in the study. For logistic reasons, only 2376 participants residing within or close to the city of Augsburg were offered an additional echocardiographic examination. The 826 men and 852 women who agreed to be examined had the same sex distribution as the nonresponders, but they differed in the following ways: they were younger (on average, by 3.2 years), their body-mass index (BMI) was lower (by 0.7 kg/m2), and their systolic blood pressure was lower (by 3.0 mm Hg) (P<0.001).
After a detailed interview, body height and weight were measured in
light clothing. BMI was computed as weight divided by height squared
(kg/m2). Obesity was defined according to the
National Institutes of Health Consensus Development Panel
criteria27 as a BMI 
27.3 kg/m2 in
men and 27.8 kg/m2 in women. Resting blood
pressure was measured in a sitting position and after a rest of 30
minutes using a Hawksley random zero sphygmomanometer. Blood pressure
was recorded 3 times in the right arm under standardized
conditions,28 and the mean of the second and third
measurement was used for this study. Hypertension was defined as a
systolic blood pressure 140 mm Hg and/or a
diastolic blood pressure 90 mm Hg or use of
antihypertensive medications.
BIA
Fat-free mass was determined by measuring bioelectrical
impedance with a Body Composition Analyzer TVI-10 (Danziger
Medical Technology). Measurements were performed under highly
standardized conditions with all subjects in a supine
position.29 30 All measurements were performed using an
alternating current with a frequency of 50 kHz and an amplitude of 800
mA. A tetrapolar placement of electrodes was used.21 This
method has been validated in previous studies against a variety of
other, more laborious techniques.20 21 22 23 Studies in
children and adults have shown that BIA can be validly applied to
assess body composition in epidemiological studies if proper
consideration is given to population-specific
characteristics.31 As reported previously,18
we used a formula derived by Heitmann.30 32
Analysis of the intraobserver and interobserver variability of
BIA measurements indicated a high reliability, with coefficients of
variation consistently below 1%.29 Body fat was
calculated by subtracting FFM from total body weight (in
kilograms).
Echocardiographic Measurements
Two-dimensional guided M-mode echocardiograms were obtained by 2
expert sonographers using the Sonos 1500 (Hewlett Packard Inc). M-mode
tracings were recorded on strip-chart paper at 50 mm/s. All
M-mode tracings were analyzed by a single cardiologist who was
blinded regarding clinical data. All measurements were made according
to the Penn convention, and left ventricular mass was
calculated by the formula described by Devereux and
Reichek.33 The rank correlation for 144 duplicate
measurements of the 2 sonographers was 0.91, and there was a mean
difference (systematic bias) between both observers of 0.9 g, with
a SD of 10.8 g.
Healthy Reference Group
Using procedures analogous to a previous report from the
Framingham Heart Study,34 a healthy reference population
was defined to generate partition values for LVH. Only M-mode tracings
with optimal visualization of left ventricular inferences
were allowed for this study. For the 825 men and 850 women with a
complete examination, the echocardiographic
recordings of 161 men and 110 women were considered technically
not adequate. Appropriate BIA measurements could not be obtained in 19
men and 30 women. Further exclusion criteria were as follows: (1)
evidence of cardiopulmonary disease by history, physical
examination, and ECG or echocardiographic evidence of
valve disease (except mitral valve prolapse) (356 men and 420 women);
(2) arterial blood pressure 140 mm Hg
systolic and/or 90 mm Hg diastolic (368 men
and 289 women); (3) taking medications for cardiopulmonary
disease (156 men and 171 women); and (4) obesity, which was defined
according to the criteria described above (326 men and 334 women). A
healthy reference group of 213 men and 291 women, with none of the
exclusion criteria, was eventually identified.
Statistical Methods
There were 653 men and 718 women with a complete set of data for
echocardiography, BIA measurements, and the other
variables. BSA was determined according to the Dubois
formula.35 Indexations of LV mass were obtained by
computing the ratios of LV mass/height, LV
mass/height2.0, LV
mass/height2.7, LV mass/BSA, and LV mass/FFM.
Because results for LV mass/height2.0 were not
qualitatively different from those for LV
mass/height2.7, they were not included in this
report. Results for continuous variables are presented as
means and SDs. Because all 4 indexed LV mass values showed an
approximately normal distribution, we derived the partition values for
LVH in the healthy reference group using the sex-specific mean value
plus 2xSD (internal criteria). The prevalence of LVH was first
estimated in the total study population by applying the internal MONICA
Augsburg partition values. For comparison, prevalences were
additionally computed using LVH partition values from the literature
(external criteria).10 12 19 34 Sex differences were
assessed by 
2 tests. Prevalence estimates were
further evaluated by 10-year age groups, in normotensives versus
hypertensives, and in those with normal weight versus the obese.
Agreement of prevalence estimates was evaluated by McNemar’s test.
Age-adjusted logistic regression analyses were used to
determine how different indexations and criteria impacted the odds
ratios for LVH in hypertension and obesity. All analysis were
performed with the SAS System for Windows, release 6.11.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Quite expectedly, the healthy reference group was substantially younger, taller, and less heavy than the total sample. The reference group had lower systolic and diastolic blood pressures, less body fat, and less LV mass. However, the values for FFM were only slightly lower in the healthy subgroup (Table 1
).
|
The criteria for the distinction of individuals with and without LVH
differed considerably by sex and type of indexation. Generally,
partition values based on indexations to height,
height2.7, and BSA were higher for men than for
women. In contrast, using LV mass/FFM produced a partition value of 4.1
g/kg, which was identical in men and women. We further noted that the
internally derived Augsburg partition values deviated, in part
substantially, from the external criteria that have been reported in
other populations (Table 2).
|
Consequently, different indexations and criteria had a considerable
impact on the estimation of LVH prevalences in the total sample. When
using internal MONICA Augsburg criteria, the prevalences ranged from
16.2% to 21.6% in men and from 17.0% to 23.7% in women (Table 3). Using external cut points, prevalence
estimates varied more drastically, from 12.4% to 28.6% in men and
from 7.0% to 29.1% in women. Except for the external FFM criteria,
all indexations estimated LVH prevalence as higher in women than in
men. We noted, however, that sex differences were not statistically
significant for any of the internal criteria but that LVH prevalences
were significantly higher in women when using external criteria for LV
mass/height and LV mass/BSA (P<0.001).
|
Internal LVH criteria were applied in all further analyses. In
each age group, indexation to height or height2.7
produced higher LVH prevalences than LV mass/FFM (Figure 1). The disagreement over all age groups
was highly significant (P<0.001). BSA-based estimates were
higher than FFM-indexed prevalences in the younger age groups and lower
in the older age groups (P=0.046). LVH prevalences among
subjects with normal blood pressures or with normal weights were
similar (P>0.20), irrespective of the type of indexation
applied. By contrast, prevalence estimates differed significantly
(P<0.01) among individuals with hypertension and obesity
when height- and height2.7-based LVH was compared
with estimates obtained with either FFM or BSA criteria (Figure 2). In multivariate
analyses including age, hypertension, and obesity as
covariates, the odds of LVH using height- and
height2.7-based indexations were raised 3.5-fold
in men and 
5.5-fold in women when comparing obese and normal-weight
individuals (Table 4). Applying FFM-based
criteria, the odds ratios were reduced to 2.1 in men and 2.5 in women.
The results for hypertensives were similar but less pronounced. In
hypertensives and the obese, odds ratios obtained with indexations to
BSA tended to be close to those obtained with FFM.
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study demonstrates that varying indexations of LV mass exert a prominent influence on the proportion of subjects identified as having LVH. Indexations to FFM largely reduced sex differences in LV mass and, in this study, resulted in identical partition values for men and women with hypertrophy. Differences between indexations were present across all age groups, but they were more pronounced among the obese and in women.
We recently suggested indexing LV mass to FFM (or lean body mass) to account for variations in body size and composition.18 Techniques to determine FFM have improved over the years, and FFM can now be easily determined by BIA.18 19 20 30 31 32 Indexation to FFM eliminates sex differences in the measurement of LV mass in children and adolescents.16 36 Thus, sex differences in cardiac size in adults may also mostly reflect differences in the hemodynamics and metabolic demands of men and women.14 15 Our findings seem to confirm that sex differences present in absolute heart size are largely attributable to different body compositions and that, per unit of FFM, men and women have similar cardiac masses.18 This contention is further supported by the identical LVH partition values derived in the healthy men and women in this study.
Few studies have been able to investigate the impact of normalization for FFM in samples from the general population. Recently, the Strong Heart Study in American Indians, which also used FFM-indexed LV mass, reported LVH criteria identical to ours.19 It must be noted, however, that this value of 4.1 g/kg was an averaged estimate derived from an LVH criterion of 4.9 g/kg in women and 3.6 g/kg in men. Thus, contrary to all previous reports, LVH criteria in the Strong Heart Study were substantially higher for women than for men. The lower body height and higher body fat content of American Indians, particularly women, may account for these striking discrepancies with our Caucasian sample.
Irrespective of age and sex, FFM indexation assigned significantly less individuals to the group with LVH than the height- and height2.7-based criteria. BSA-based estimates were closer to FFM results, but they were significantly higher with young age and significantly lower with older age. Interestingly, the frequency of LVH was similar in normotensive and normal weight subjects, irrespective of the type of indexation applied. Significant differences occurred among hypertensives and, more markedly, among the obese, especially in women. Allometric signals and indexations to height have been introduced in the past to eliminate a "forgiveness for obesity" that is supposedly associated with indexations for BSA.11 12 14 34 Our suggestion to use FFM indexations might be similarly reproached. Clearly, using a measure of adult height for indexation implicitly denies that body composition is a relevant determinant of LV mass because it ignores that weight differences in subjects of the same height can either result from a more athletic or from a more adipose body habitus. Thus, although adaptive LV mass increments in the former may be considered appropriate, they should be rated as potentially adverse in the latter instance. We contend here that only FFM indexation permits the distinction between gains of fat-free mass and those of fat mass and, thus, it can attribute changes in LV mass accordingly.
In this context, in must be noted that in obese individuals, fat mass and FFM are raised. Thus, the age-adjusted difference in FFM between obese and nonobese subjects in our study was 5 kg in men and 4.2 kg in women, with contrasting related differences in fat mass of 10 kg and 15 kg, respectively. The mechanisms underlying the rise of fat-free mass in the obese are still poorly understood, and it is not clear whether the increase of FFM in obesity and the subsequent cardiac response is indeed prognostically benign. To obtain conclusive evidence in this regard, the impacts of normalizing LV mass for FFM in obese individuals must be evaluated in prospective studies.
We attempted to replicate as closely as possible the procedures used in
the Framingham Heart Study to generate criteria for LVH.34
However, our internal partition values for LV mass/BSA and LV
mass/height differed notably from their cut points (Table
>2).
Using Framingham criteria, LVH was estimated to be significantly more
frequent in women than in men. However, such a marked excess of LVH in
Augsburg women does not seem very likely because hypertension and
obesity, the major determinants of LVH, have been consistently
more prevalent in men than in women for at least a
decade.37 The internal partition values for LV
mass/height2.7 also differed from the external
criteria, especially in men. This can perhaps be explained by the fact
that the external criteria were derived in a multiethnic population, of
which 36% were African-Americans.12 14 Finally, the
application of the FFM-based criteria of the Strong Heart Study led to
prevalence estimates for the Augsburg sample that were highly
inconsistent with all other estimates (Table 3). Our
analyses suggest that the indiscriminate adoption of external
criteria for LVH may be grossly misleading, and we propose using
internally derived partition values whenever possible.
There are limitations to this study. In particular, technically adequate echocardiography and BIA requirements caused some selection.38 The impact of this selection is difficult to assess, but it is reassuring to note that our healthy reference group was, for most characteristics, similar to that selected in an analogous way from the Framingham Heart Study.34
We conclude that FFM seems physiologically appropriate for LV mass indexation. Its use results in significantly lower proportions of individuals with LVH in the population, in particular among hypertensives and the obese. We propose that FFM-indexed partition values of LVH be derived in other populations and that the prognostic significance of these values, including that in subgroups such as the obese, be evaluated in prospective studies.
|
Acknowledgments |
|---|
This work was supported by grant 01GB9403 from the Bundesministerium für Bildung und Forschung.
Received December 1, 1999; revision received February 23, 2000; accepted February 24, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173–178.
2. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345–352.
3. Ghali JK, Liao Y, Simmons B, et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:831–836.
4.
Liao Y, Cooper RS, Mensah GA, et al. Left
ventricular hypertrophy has a greater impact on
survival in women than in men. Circulation. 1995;92:805–810.
5. Liao Y, Cooper RS, Durazo-Arzivu R, et al. Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol. 1997;26:641–647.
6. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence, and mortality in the Framingham Study. Ann Intern Med. 1969;71:89–105.
7. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–1566.[Abstract]
8. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25:879–844.[Abstract]
9.
Haider AW, Larson MG, Benjamin EJ, et al. Increased
left ventricular mass and hypertrophy are
associated with increased risk for sudden death. J Am Coll
Cardiol. 1998;32:1454–1459.
10. Abergel E, Tase M, Bohlender J, et al. Which definition for echocardiographic left ventricular hypertrophy? Am J Cardiol. 1995;75:498–502.[Medline] [Order article via Infotrieve]
11. Levy D, Anderson KM, Savage DD, et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med. 1988;108:7–13.
12. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251–1260.[Abstract]
13.
Lauer MS, Anderson KM, Kannel WB, et al. The impact of
obesity on left ventricular mass and geometry: the
Framingham Heart Study. JAMA. 1991;266:231–236.
14.
de Simone G, Devereux RB, Roman MJ, et al. Relation of
obesity and gender to left ventricular
hypertrophy in normotensive and hypertensive adults.
Hypertension. 1994;23:600–606.
15. de Simone G, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056–1062.[Abstract]
16. Daniels SR, Kimball TR, Morrison JA, et al. Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. J Am Coll Cardiol. 1995;76:699–701.
17. Hammond IW, Devereux RB, Alderman MH, et al. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adults. J Am Coll Cardiol. 1988;12:996–1004.[Abstract]
18.
Hense HW, Gneiting B, Muscholl M, et al. The
associations of body size and body composition with left
ventricular mass: impacts for indexation in adults.
J Am Coll Cardiol. 1998;32:451–457.
19.
Bella JN, Devereux RB, Roman MJ, et al, for the Strong
Heart Study Investigators. Relations of left ventricular
mass to fat-free and adipose mass: the Strong Heart Study.
Circulation. 1998;98:2538–2544.
20. Kushner R. Bioelectrical impedance analysis: a review of principles and applications. J Am Coll Nutr. 1992;11:199–209.[Abstract]
21. Fuller NJ. Comparison of abilities of various interpretations of bio-electrical impedance to predict reference method body composition assessment. Clin Nutr. 1993;12:236–242.
22.
Segal KR, Van Loan M, Fitzgerald PI, et al. Lean body
mass estimation by bioelectrical impedance analysis: a
four-site cross-validation study. Am J Clin Nutr. 1988;47:7–14.
23. Franssila Kalunki A. Comparison of near-infrared light spectroscopy, bioelectrical impedance and tritiated water techniques for the measurement of fat-free mass in humans. Scand J Clin Lab Invest. 1992;52:879–885.[Medline] [Order article via Infotrieve]
24. WHO MONICA. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration: WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41:105–114.[Medline] [Order article via Infotrieve]
25. Keil U, Stieber J, Döring A, et al. The cardiovascular risk factor profile in the study area Augsburg: results from the first MONICA survey 1984/85. Acta Med Scand Suppl. 1988;728:119–128.[Medline] [Order article via Infotrieve]
26. Chambless L, Cairns V, Herbold M. MONICA Augsburg Survey Sampling. GSF Bericht 31/86. München, Germany: Gesellschaft für Strahlen- und Umweltforschung; 1987.
27. National Institutes of Health Consensus Development Panel on the Health Implication of Obesity. Ann Intern Med. 1991;114:202–209.
28. Hense HW, Koivisto AM, Kuulasmaa K, et al, for the WHO MONICA Project. Assessment of blood pressure measurement quality in the baseline surveys of the WHO MONICA Project. J Hum Hypertens. 1995;9:935–946.[Medline] [Order article via Infotrieve]
29. Kussmaul B, Döring A, Filipiak B. Bioelektrische Impedanzanalyse (BIA) in einer epidemiologischen Studie. Ernährungs-Umschau. 1996;43:46–48.
30. Heitmann B. Prediction of body water and fat in adult Danes from measurement of electrical impedance: a validation study. Int J Obesity. 1990;14:789–802.[Medline] [Order article via Infotrieve]
31. Deurenberg P, Kusters C, Smit H. Is the bioelectrical impedance method suitable for epidemiological field studies? Eur J Clin Nutr. 1989;43:647–654.[Medline] [Order article via Infotrieve]
32. Heitmann B. Body fat in adult Danish population aged 35–65 years: an epidemiological study. Int J Obesity. 1991;15:535–545.[Medline] [Order article via Infotrieve]
33.
Devereux RB, Reichek N.
Echocardiographic determination of left
ventricular mass in man: anatomic validation of the method.
Circulation. 1977;55:613–618.
34. Levy D, Savage DD, Garrison RJ, et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;59:956–960.[Medline] [Order article via Infotrieve]
35. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1961;17:863–871.
36.
Daniels SR, Kimball TR, Morrison JA, et al. Effect of
lean body mass, fat mass, blood pressure, and sexual maturation on left
ventricular mass in children and adolescents.
Circulation. 1995;92:3249–3254.
37. Hense HW, Filipiak B, Döring A, et al. Ten-year trends of cardiovascular risk factors in the MONICA Augsburg Region in Southern Germany. CVD Prev. 1998;1:318–327.
38. Whalley GA, Gamble GD, Doughty RN, et al. Selection bias in clinical research when subjects are excluded because of failure to estimate left ventricular mass by echocardiography. J Am Soc Echocardiogr. 1998;11:1050–1055.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  W. Lieb, B. Mayer, J. Stritzke, A. Doering, H.-W. Hense, H. Loewel, J. Erdmann, and H. Schunkert Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: The MONICA/KORA Augsburg Echocardiographic Substudy Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2780 - 2787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Valle, E. Bagolin, C. Canali, P. Giovinazzo, S. Barro, N. Aspromonte, E. Carbonieri, and L. Milani The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients Eur J Echocardiogr, January 1, 2006; 7(1): 40 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.v. Lukowicz, M. Fischer, H.W. Hense, A. Doring, J. Stritzke, G. Riegger, H. Schunkert, and A. Luchner BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy Eur J Heart Fail, June 1, 2005; 7(4): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. de Simone, K. Wachtell, V. Palmieri, D. A. Hille, G. Beevers, B. Dahlof, U. de Faire, F. Fyhrquist, H. Ibsen, S. Julius, et al. Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy: The LIFE (Losartan Intervention For Endpoint reduction in hypertension) Study Circulation, April 19, 2005; 111(15): 1924 - 1931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dorr, B. Wolff, D. M. Robinson, U. John, J. Ludemann, W. Meng, S. B. Felix, and H. Volzke The Association of Thyroid Function with Cardiac Mass and Left Ventricular Hypertrophy J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 673 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Peterson, P. Herrero, K. B. Schechtman, S. B. Racette, A. D. Waggoner, Z. Kisrieva-Ware, C. Dence, S. Klein, J. Marsala, T. Meyer, et al. Effect of Obesity and Insulin Resistance on Myocardial Substrate Metabolism and Efficiency in Young Women Circulation, May 11, 2004; 109(18): 2191 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fischer, A. Baessler, H.W. Hense, C. Hengstenberg, M. Muscholl, S. Holmer, A. Doring, U. Broeckel, G. Riegger, and H. Schunkert Prevalence of left ventricular diastolic dysfunction in the community: Results from a Doppler echocardiographic-based survey of a population sample Eur. Heart J., February 2, 2003; 24(4): 320 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Muntner, J. He, E. J. Roccella, and P. K. Whelton The Impact of JNC-VI Guidelines on Treatment Recommendations in the US Population Hypertension, April 1, 2002; 39(4): 897 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zoccali, F. A. Benedetto, F. Mallamaci, G. Tripepi, G. Giacone, A. Cataliotti, G. Seminara, B. Stancanelli, and L. S. Malatino Prognostic Impact of the Indexation of Left Ventricular Mass in Patients Undergoing Dialysis J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2768 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J R Hildick-Smith and L M Shapiro Echocardiographic differentiation of pathological and physiological left ventricular hypertrophy Heart, June 1, 2001; 85(6): 615 - 619. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||